A. Vincent

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière et al. · Cancer Discovery · 2021 · 560 citations · Full text

Medicine, Oncology, Pharmacology +17

Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection

Robert J. Downey, Timothy Akhurst, Mithat Gönen et al. · Journal of Clinical Oncology · 2004 · 360 citations

Medicine, Oncology, Surgery +17

Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial

Raja M. Flores, Lee M. Krug, Kenneth E. Rosenzweig et al. · Journal of Thoracic Oncology · 2006 · 145 citations · Full text

Medicine, Oncology, Surgery +14

Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial

Raja M. Flores, Lee M. Krug, Kenneth E. Rosenzweig et al. · Journal of Thoracic Oncology · 2006 · 110 citations

Medicine, Oncology, Surgery +14

Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.

Prasad S. Adusumilli, Marjorie G. Zauderer, Valerie W. Rusch et al. · Journal of Clinical Oncology · 2019 · 92 citations

Pharmacy, Immunology, Oncology +17